Moreover, CIP2A knockdown may sensitize metastatic castration-resistant prostate cancer cells to cabazitaxel chemotherapy.17 Liu and colleagues18 also showed that CIP2A knockdown increased the drug sensitivity of HeLa and doxorubicin-resistant HeLa cells. This evidence concerns the gene CIP2A and prostate carcinoma.